Skip to main content
. 2025 Jan 8;104(3):1329–1351. doi: 10.1007/s00277-024-06143-7

Table 4.

Activity of Isa/Dara-KRd in patients with NDMM not receiving ASCT

Study Median follow-up, mo ORR, % Best response, % MRD–, % MRD– by cytogenetics, % Median (95% CI) PFS, mo PFS rate
(95% CI), %
Median (95% CI) OS, mo OS rate
(95% CI), %
High risk Standard risk
Isa-KRd
GMMG-CONCEPTa[41] 33

89

(post-consolidation)

• ≥ VGPR: 89

• ≥ CR: 58

54 (10–5)

69 (10–5) at any time point

54/46 (≥ 6/ ≥ 12 mo sustained MRD–)

54 (10–5) N/A Not reached

• 1-y:

75 (60–95)

• 2-y:

63 (46–85)

• 3-y:

58 (42–82)

Not reached

• 1-y:

84 (70–100)

• 2-y:

71 (55–92)

SKylaRkb[[42,54]] 26 100

C8:

• ≥ VGPR: 98

• ≥ CR: 65

(post-consolidation)

C8: 72 (10–5)

19 (10–6)

NR NR NR

• 1-y:

98 (86–100)

• 2-y:

91 (83–100)

NR

• 1-y:

98 (86–100)

• 2-y:

96 (90–100)

Dara-KRd
GEM2017FIT[48] 33

VMP-Rd: 87 (P < 0.0001)

Dara-KRd: 89 (P < 0.0001)

KRd: 89

(P < 0.0001)

(end of induction)

 ≥ CR:

• VMP-Rd: 40 (P < 0.0001)

• Dara-KRd: 61 (P < 0.0001)

• KRd: 59 (P < 0.0001)

(10–5)

• VMP-Rd: 32 (P < 0.0001)

• Dara-KRd: 79 (P < 0.0001)

• KRd: 69 (P < 0.0001)

(10–6)

• VMP-Rd: 24 (P < 0.0001)

• Dara-KRd: 75 (P < 0.0001)

• KRd: 59 (P < 0.0001)

NR NR NR

18 mo:

• VMP-Rd: 79

• Dara-KRd: 87

• KRd: 87

NR

18 mo:

• VMP-Rd: 91

• Dara-KRd: 90

• KRd: 95

MANHATTAN[49] 20.3 (95% CI, 19–22)

100

(end of C8)

• ≥ VGPR: 95

• ≥ CR: 95

71 (54–83) (10–5)

88 (1-y sustained MRD–)c

OR, 1.7 (95% CI, 0.36–8.6); P = 0.50 vs standard risk N/A NR

1-y:

98 (93–100)

NR 1-y: 100
UC-IRB17-1097[50] 27

95

(end of C8 induction)

sCR and/or MRD–: 75 (95% CI, 61–89)

• ≥ VGPR: 95

• sCR: 68

59 (10–5)

35 (10–6)

Best MRD– 65 (10–5), 53 (10–6)

40 (1-y sustained MRD–)d

NR NR NR

3-y: 85

• 0 HRCA: 100

• 1 HRCA: 92

• ≥ 2 HRCAs: 60

NR 3-y: 95
MMY1001[51] 23.3 (6.9–27.7)

100

(end of C13)

• ≥ VGPR: 86

• ≥ CR: 67

75 (10–5)

(for 6 of 8 patients who achieved ≥ CR)

NR NR Not reached

1-y:

95 (71–99)

NR NR

ASCT, autologous stem cell transplant; C, cycle; CR, complete response; d, dexamethasone; Dara, daratumumab; HRCA, high-risk cytogenetic abnormalities; Isa, isatuximab; ITT, intention-to-treat; K, carfilzomib; MRD, minimal residual disease; N/A, not applicable; NDMM, newly diagnosed multiple myeloma; NR, not reported; OR, odds ratio; ORR, overall response rate; OS, overall survival; PFS, progression-free survival; R, lenalidomide; sCR, stringent complete response; SCT, stem cell transplant; VGPR, very good partial response; VMP, bortezomib, melphalan, and prednisone

a26 patients were transplant ineligible

bThe SKylaRk trial included transplant-eligible patients, but SCT was deferred in most patients (89%; 40/45 patients who were evaluable after induction and consolidation). A total of 36 patients completed C8 of therapy and were evaluable for MRD measurement. PFS and OS were evaluated in the ITT population (N = 50)

cPatients who were assessed for MRD at 1-y follow-up

dMRD < 10–5 on two or more instances ≥ 1 y apart. The denominator includes patients with trackable MRD and ≥ 1 y of MRD follow-up if they had at least one MRD negative result